Effects of SGLT2 Inhibitors with and without Metformin in High-Risk, Treatment-Naïve Patients with Diabetes

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1<scp>Sodium‐glucose co‐transporter‐2</scp> inhibitors with and without metformin: A meta‐analysis of cardiovascular, kidney and mortality outcomes2020 · 78 citations
2. 2Cardiovascular Safety of Sodium Glucose Cotransporter 2 Inhibitors as Add-on to Metformin Monotherapy in Patients with Type 2 Diabetes Mellitus2020 · 15 citations
3. 3Impact of SGLT2 Inhibitors on Multiple Cardiometabolic Risk Factors: A Retrospective Cohort Study2026
4. 4Sodium Glucose Transporter 2 Inhibitors Versus Metformin on Cardiovascular and Renal Outcomes in Patients With Diabetes With Low Cardiovascular Risk: A Nationwide Cohort Study2024 · 4 citations
5. 5937-P: Efficacy and Safety of SGLT2i vs. Other Oral Antidiabetic Drugs as Dual Therapy Add-On to Metformin in Type 2 Diabetes—A Systematic Review and Meta-analysis2024